Newswise News from Yale Cancer Center/Smilow Cancer Hospital Latest news from Yale Cancer Center/Smilow Cancer Hospital on Newswise en-us Copyright 2024 Newswise Newswise News from Yale Cancer Center/Smilow Cancer Hospital 115 31 / /images/newswise-logo-rss.gif Botanical medicine reduces rectal cancer treatment side effects that can sideline surgeries /articles/botanical-medicine-reduces-rectal-cancer-treatment-side-effects-that-can-sideline-surgeries/?sc=rsin /articles/botanical-medicine-reduces-rectal-cancer-treatment-side-effects-that-can-sideline-surgeries/?sc=rsin Fri, 09 Aug 2024 17:05:04 EST Ancient Chinese traditional medicine significantly reduces the side effects of rectal cancer treatments that, in some patients, can be so toxic that treatment must be paused, or stopped, which diminishes its effectiveness. Yale Cancer Center/Smilow Cancer Hospital Treatment for Recurrent Uterine Cancer Advances to Next Research Phase /articles/treatment-for-recurrent-uterine-cancer-advances-to-next-research-phase/?sc=rsin /articles/treatment-for-recurrent-uterine-cancer-advances-to-next-research-phase/?sc=rsin Wed, 31 Jul 2024 16:05:40 EST The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a phase III trial. Yale Cancer Center/Smilow Cancer Hospital Yale New Haven Hospital nationally ranked in 11 specialties by U.S. News & World Report /articles/yale-new-haven-hospital-nationally-ranked-in-11-specialties-by-u-s-news-world-report/?sc=rsin /articles/yale-new-haven-hospital-nationally-ranked-in-11-specialties-by-u-s-news-world-report/?sc=rsin Wed, 17 Jul 2024 09:05:45 EST In addition to earning the sixth spot nationally in Psychiatry, Yale New Haven Hospital ranked well in Obstetrics and Gynecology (#19), Otolaryngology (Ear Nose and Throat) (#27), Geriatrics (#28), Diabetes and Endocrinology (#29) Pulmonology and Lung Surgery (#31), Urology (#31), Heart and Heart Surgery (#43) Cancer (#45), Neurology and Neurosurgery (#48) and Gastroenterology and GI Surgery (#50). Yale Cancer Center/Smilow Cancer Hospital Yale Scientists Develop Potential Stealth Cancer Therapy /articles/yale-scientists-develop-potential-stealth-cancer-therapy/?sc=rsin /articles/yale-scientists-develop-potential-stealth-cancer-therapy/?sc=rsin Mon, 15 Jul 2024 15:05:53 EST Sneaking by cancer's defenses, by disguising tumor-fighting antibodies inside the molecules cancer uses to nourish tumor growth, is the basis of a novel therapy from Yale Cancer Center researchers at the Yale School of Medicine (YSM). Yale Cancer Center/Smilow Cancer Hospital Chemotherapy Before Surgery Benefits Some Patients with Pancreatic Cancer /articles/chemotherapy-before-surgery-benefits-some-patients-with-pancreatic-cancer/?sc=rsin /articles/chemotherapy-before-surgery-benefits-some-patients-with-pancreatic-cancer/?sc=rsin Thu, 20 Jun 2024 13:05:58 EST Patients with pancreatic cancer who received chemotherapy both before and after surgery experienced longer survival rates than would be expected from surgery followed by chemotherapy, according to a new study from researchers at Yale Cancer Center (YCC) and Yale School of Medicine. The study, published June 20 in JAMA Oncology, included patients with pancreatic ductal adenocarcinoma (PDAC), which accounts for 90% of pancreatic cancers. Yale Cancer Center/Smilow Cancer Hospital Promising New Treatment for Patients with HR+ HER-2 Negative Metastatic Breast Cancer /articles/promising-new-treatment-for-patients-with-hr-her-2-negative-metastatic-breast-cancer/?sc=rsin /articles/promising-new-treatment-for-patients-with-hr-her-2-negative-metastatic-breast-cancer/?sc=rsin Thu, 30 May 2024 15:05:56 EST New research from Yale Cancer Center reveals first-of-its-kind data from a phase I study in patients with hormone receptor positive HER2-negative metastatic breast cancer. The results, which assess the safety and efficacy of a treatment known as PF-07248144, offer new hope for treating this aggressive type of breast cancer. Yale Cancer Center/Smilow Cancer Hospital ARC-9: A randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC). /articles/arc-9-a-randomized-study-to-evaluate-etrumadenant-based-treatment-combinations-in-previously-treated-metastatic-colorectal-cancer-mcrc/?sc=rsin /articles/arc-9-a-randomized-study-to-evaluate-etrumadenant-based-treatment-combinations-in-previously-treated-metastatic-colorectal-cancer-mcrc/?sc=rsin Wed, 29 May 2024 21:05:40 EST Yale Cancer Center/Smilow Cancer Hospital A phase 1 dose expansion study of a first-in-class KAT6 inhibitor (PF-07248144) in patients with advanced or metastatic ER+ HER2− breast cancer. /articles/a-phase-1-dose-expansion-study-of-a-first-in-class-kat6-inhibitor-pf-07248144-in-patients-with-advanced-or-metastatic-er-her2-breast-cancer/?sc=rsin /articles/a-phase-1-dose-expansion-study-of-a-first-in-class-kat6-inhibitor-pf-07248144-in-patients-with-advanced-or-metastatic-er-her2-breast-cancer/?sc=rsin Wed, 29 May 2024 21:05:37 EST Yale Cancer Center/Smilow Cancer Hospital ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study. /articles/arv-766-a-proteolysis-targeting-chimera-protac-androgen-receptor-ar-degrader-in-metastatic-castration-resistant-prostate-cancer-mcrpc-initial-results-of-a-phase-12-study/?sc=rsin /articles/arv-766-a-proteolysis-targeting-chimera-protac-androgen-receptor-ar-degrader-in-metastatic-castration-resistant-prostate-cancer-mcrpc-initial-results-of-a-phase-12-study/?sc=rsin Wed, 29 May 2024 21:05:23 EST Yale Cancer Center/Smilow Cancer Hospital A Promising New Targeted Therapy for Patients with Metastatic Prostate Cancer with Therapy-Resistant Mutations /articles/a-promising-new-targeted-therapy-for-patients-with-metastatic-prostate-cancer-with-therapy-resistant-mutations/?sc=rsin /articles/a-promising-new-targeted-therapy-for-patients-with-metastatic-prostate-cancer-with-therapy-resistant-mutations/?sc=rsin Wed, 29 May 2024 11:05:55 EST Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy. Yale Cancer Center/Smilow Cancer Hospital Reducing Radiation After Surgery Prolongs Survival for Some Patients With HPV-Related Throat Cancer /articles/reducing-radiation-after-surgery-prolongs-survival-for-some-patients-with-hpv-related-throat-cancer/?sc=rsin /articles/reducing-radiation-after-surgery-prolongs-survival-for-some-patients-with-hpv-related-throat-cancer/?sc=rsin Wed, 29 May 2024 11:05:48 EST Patients being treated for HPV-related oropharynx cancer might need less radiation therapy typically given post-surgery, according to a new study. Yale Cancer Center/Smilow Cancer Hospital New Survival Data From a Lung Cancer Study to be Revealed by Yale Cancer Center Expert at International Conference /articles/new-survival-data-from-a-lung-cancer-study-to-be-revealed-by-yale-cancer-center-expert-at-international-conference/?sc=rsin /articles/new-survival-data-from-a-lung-cancer-study-to-be-revealed-by-yale-cancer-center-expert-at-international-conference/?sc=rsin Fri, 24 May 2024 11:05:45 EST "The COAST study, which we began five years ago, involves patients who get chemotherapy and radiation therapy for lung cancer. And now we know that we can improve the outcome with a drug called durvalumab," explained Dr. Herbst, who will present the findings at ASCO. Yale Cancer Center/Smilow Cancer Hospital Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer. /articles/development-and-validation-of-rsclin-n-tool-for-hormone-receptor-positive-hr-her2-negative-her2-node-positive-breast-cancer/?sc=rsin /articles/development-and-validation-of-rsclin-n-tool-for-hormone-receptor-positive-hr-her2-negative-her2-node-positive-breast-cancer/?sc=rsin Tue, 21 May 2024 21:05:23 EST Yale Cancer Center/Smilow Cancer Hospital Oncologists should re-evaluate cancer treatments near end of life /articles/oncologists-should-re-evaluate-cancer-treatments-near-end-of-life/?sc=rsin /articles/oncologists-should-re-evaluate-cancer-treatments-near-end-of-life/?sc=rsin Thu, 16 May 2024 11:05:40 EST The study, which joins a growing body of research on end-of-life cancer treatment, published May 16 in JAMA Oncology. Yale Cancer Center/Smilow Cancer Hospital New Research and Treatment Advances From Yale Cancer Center to Be Presented at the World's Largest Cancer Research Conference /articles/new-research-and-treatment-advances-from-yale-cancer-center-to-be-presented-at-the-world-s-largest-cancer-research-conference2/?sc=rsin /articles/new-research-and-treatment-advances-from-yale-cancer-center-to-be-presented-at-the-world-s-largest-cancer-research-conference2/?sc=rsin Mon, 13 May 2024 12:05:13 EST Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. Yale Cancer Center/Smilow Cancer Hospital New Research and Treatment Advances From Yale Cancer Center to be Presented at the World's Largest Cancer Research Conference /articles/new-research-and-treatment-advances-from-yale-cancer-center-to-be-presented-at-the-world-s-largest-cancer-research-conference/?sc=rsin /articles/new-research-and-treatment-advances-from-yale-cancer-center-to-be-presented-at-the-world-s-largest-cancer-research-conference/?sc=rsin Mon, 13 May 2024 11:05:20 EST Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed "The Art and Science of Cancer Care: From Comfort to Cure" will include over 200 sessions. Yale Cancer Center/Smilow Cancer Hospital Yale Cancer Center Earns International Reaccreditation for Expertise in CAR T-cell Therapy and Stem Cell Transplantation /articles/yale-cancer-center-earns-international-reaccreditation-for-expertise-in-car-t-cell-therapy-and-stem-cell-transplantation/?sc=rsin /articles/yale-cancer-center-earns-international-reaccreditation-for-expertise-in-car-t-cell-therapy-and-stem-cell-transplantation/?sc=rsin Tue, 07 May 2024 16:05:40 EST Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) have again received an internationally recognized accreditation for cellular therapy and stem cell transplantation from the Foundation for the Accreditation of Cellular Therapy (FACT), giving patients life-saving cancer treatment options in Connecticut. Yale Cancer Center/Smilow Cancer Hospital Study Uncovers At Least One Cause of Roadblocks to Cancer Immunotherapy /articles/study-uncovers-at-least-one-cause-of-roadblocks-to-cancer-immunotherapy/?sc=rsin /articles/study-uncovers-at-least-one-cause-of-roadblocks-to-cancer-immunotherapy/?sc=rsin Mon, 06 May 2024 09:05:43 EST A study led by Yale scientists, published April 25 in the journal Science Immunology, investigated the potential causes associated with T cell exclusion using a genome-wide screen of more than 1,000 human proteins. Yale Cancer Center/Smilow Cancer Hospital 109 Yale Cancer Center and Smilow Cancer Hospital physicians recognized as 'Top Doctors' in Connecticut /articles/109-yale-cancer-center-and-smilow-cancer-hospital-physicians-recognized-as-top-doctors-in-connecticut/?sc=rsin /articles/109-yale-cancer-center-and-smilow-cancer-hospital-physicians-recognized-as-top-doctors-in-connecticut/?sc=rsin Wed, 01 May 2024 13:05:09 EST Connecticut Magazine released its "Top Doctors" issue today, listing some of the state's best physicians, who provide exceptional care for patients. This year's list includes 109 Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) physicians, a 35% increase in "Top Doctors" for SCH and YCC from last year. Yale Cancer Center/Smilow Cancer Hospital Topical shows promise in treating precancerous cervical condition /articles/topical-shows-promise-in-treating-precancerous-cervical-condition/?sc=rsin /articles/topical-shows-promise-in-treating-precancerous-cervical-condition/?sc=rsin Tue, 09 Apr 2024 12:05:50 EST Cervical cancer, often caused by persistent human papillomavirus (HPV) infections, remains a public health challenge worldwide despite falling diagnoses related to the success of the HPV vaccine[GR1] in young adult women. Yale Cancer Center/Smilow Cancer Hospital